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Highly solvatochromic and tunable fluorophores based on a 4,5-
quinolimide scaffold: Novel CDK5 probes§,†
Juan A. González-Vera,ab Francisco Fueyo-González,a Ibon Alkorta,a Marion Peyressatre,b May C. 
Morris,b and Rosario Herranz*a
Novel 4,5-quinolimide-based fluorophores are more 
solvatochromic and red-shifted than known naphthalimide 
analogues. Conjugation of one of these fluorophores to a peptide 
derived from CDK5 kinase demonstrated its sensitivity for 
monitoring the interaction with its regulatory partner p25. 
Introduction of the quinolimide-labelled peptide into living 
glioblastoma cells probed the interaction with endogenous p25. 
Solvatochromic fluorophores have been used in the design of 
biosensors with applications ranging from the study of protein 
structural dynamics to the detection of protein-binding 
interactions.1 Among these fluorophores, 1,8-naphthalimide 
derivatives have recently attracted considerable interest, due 
to their small size and their favorable photophysical 
properties.2 These derivatives exhibit very weak fluorescence 
in water and polar solvents, compared to that in non-polar 
environments. This highly solvatochromic behavior confers 
advantage of high signal-to-noise ratio for detection of 
molecular interactions.1a, 1c 1,8-Naphthalimide-based 
fluorophores have found wide application in pH,3 cation2c and 
anion2a chemosensors, DNA binders and anticancer agents,2b
or as reporters of biomolecular interactions1a-c and cellular 
imaging agents.2b, 4 One shortcoming of many of these sensors 
is their limited solubility in water.1a Taking into account that 
introduction of a protonatable nitrogen atom into the 1,8-
naphthalimide scaffold could increase water solubility and red-
shift the fluorescence emission,5 along with the prevalence of 
the quinoline core in diverse fluorescence sensors,6 we 
decided to explore the fluorescence properties of chimeric 
naphthalimide-quinoline fluorophores (Figure 1, B) and their 
potential for developing probes to monitor protein/protein 
interactions. In this study we have investigated the utility of 
chimeric naphthalimide-quinoline fluorophores, to 
characterize the interaction between two peptides derived 
from the main interface between CDK5 kinase and its 
regulatory partner p25. Recent studies suggest that CDK5 
expression and hyperactivation are involved in glioblastoma 
and correlate with the pathological grade of gliomas.7
However, up to now, there are no available tools to monitor 
the CDK5/p25 interaction in its native environment. The crystal 
structure of this neurospecific kinase complex indeed shows 
that CDK5 binds p25 through the same interface as other 
CDKs, namely the C helix.8 However, the affinity of this 
interface has not been characterized compared to that of 
other CDK/Cyclin complexes, such as CDK2/Cyclin A or 
CDK4/Cyclin D1. We show herein that one of the quinolimides 
herein described constitutes a much more sensitive probe for 
monitoring these peptide/peptide interactions than other 
standard dyes. Finally, we show that internalization of the 
quinolimide-conjugated peptide derived from CDK5 into 
cultured glioblastoma cells, provides means of localizing 
endogenous p25. 
Fig. 1  
To the best of our knowledge only two articles9 and a 
recent patent10 have previously reported on the synthesis and 
biological activity of 4,5-quinolimide (4H-benzo[de][2,6]-
naphthyridine-4,6(5H)-dione) derivatives. However, nothing 
about their fluorescence properties has been described yet 
and the synthetic methods used for the building of the 
quinolimide scaffold in these references are rather different 
from those herein described. 
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Scheme 1 Synthesis of quinolimide derivatives 16-27. Reagents and conditions: 
(a) (EtO)2OPCH2CO2H, HATU, DIPEA, CH2CL2, rt, 76 %; (b) ClCOCH2CO2Me, DIPEA, 
CH2CL2, rt, 100 %; (c) LiCl, DBU, THF, rt, 100 %; (d) K2CO3, MeOH, 70 ºC, 98%; (e) 
NaOH, H2O, 100 ºC, 100%; (f) 180 ºC, DMF, 86%; (g) POCl3, 110 ºC, 96-100%; (h) 
H2, 10% Pd(C), MeOH, rt, 100%; (i) CrO3, (5:1) Ac2O/AcOH, 110 ºC, 89-93%; (j) 
H2N-R
4, EtOH, MW 120 ºC, 29-81%; (k) TFA, dioxane, rt, 100%; (l) Fmoc-OSu, 
dioxane, rt, 71-78%. 
As shown in Scheme 1, we devised a synthetic pathway 
starting for 4,5-quinolimides B starting from the 2,3-dihydro-
1H-inden-1-one 111. Under reported conditions11 (NaH, THF, 50 
ºC, 2h), the intramolecular Wittig-Horner reaction of amide 2
led to a mixture of the cycled phosphonate 5 as major product 
(67%), along with the unsubtituted compound 4 (11%). 
However, when the cyclization was carried out with DBU/LiCl 
in THF at room temperature the  phosphonate 5 was obtained 
quantitatively. On the other hand, the unsubstituted 
quinolinone derivative 4 was obtained in 84% overall yield 
from the amide 3, by intramolecular aldol reaction, followed 
by ester saponification and decarboxylation. Aromatization of 
the 4,5-dihydrocyclopenta[de]quinolin-2(1H)-ones 4 and 5, by 
reaction with POCl3, led to the 2-chloro-quinoline derivatives 8
and 9, whose catalytic hydrogenation produced  the quinoline 
derivatives 10 and 11 in excellent yields. Then, oxidation of 8-
11 by CrO3 in (6:1) Ac2O/AcOH at 110 ºC gave the 
corresponding anhydrides 12-15. These anhydrides were not 
stable to silica gel of chromatography. Therefore, 12-15 were 
used for the quinolimide synthesis without further purification, 
after a thorough removal of chromium derivatives by filtration 
through Clarcel®. Reaction of anhydrides 12-15 with the 
corresponding amine unther MW activated heating at 100 ºC 
in EtOH yielded the desired quinolimide derivatives 16-27 in 
medium to good yields. Among these compounds, it is 
interesting to note the synthesis of the -amino-alanine 
derivatives 22-25 as tools for the preparation of fluorophore-
containing peptides. Furthermore, the ethylendiamines 26
and 27 were used for the preparation of thiol-reactive 
flourophores, the bromomethyl acetamides 28 and 29
(Scheme 2). 
Scheme 2 Synthesis of the thiol-reactive bromomethyl acetamides 28 and 29
The UV absorption and fluorescence properties of all 
synthesized quinolimide derivatives 16-26 were determined in 
solvents of varying polarity. The naphthalimide analogue A1
[Figure 1, A, R4 = (CH2)2OH] was also synthesized
12 for 
comparison purposes. The photophysical data of this reference 
compound and those of 16-19, as quinolimide models, are 
summarized in Table 1. The UV studies show that replacement 
of the naphathalimide core by the quinolimide one (A1 vs 16) 
produced a small bathochromic shift (4-15 nm) in the max
abs
and, except in water, a 30-35% decrease in the extinction 
coefficient. Introduction of the phosphonate group into the 
quinolimide scaffold (17 vs 16 and 19 vs 18), induced a 
significant bathochromic shift of 17-22 nm in the max
abs.  
Regarding the fluorescence properties, the quinolimide 
derivatives showed a greater solvatochromism than the 
naphthalimide A1. A shift of 48 nm toward the red was 
observed in the max
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Table 1. Photophysical properties of the naphthalimide A1 and quinolimide derivatives 
16-19
compda solvent lmaxabs (nm) e (M-1cm-1) lmaxem (nm) FF b
A1 toluene 362 12251 425 0.64 
dioxane 360 12085 425 0.61 
MeOH 366 12794 442 0.57 
DMSO 368 11898 442 0.47 
H2O 377 6770 457 0.61 
In vacuumc 346  390  
16 toluene 377 7873 455 0.90 
dioxane 372 8649 460 0.67 
MeOH 375 6760 490 0.28 
DMSO 377 6849 490 0.03 
H2O 381 8776 503 0.04 
In vacuumc 365  434  
17 toluene 395 4939 484 0.46 
dioxane 390 4252 487 0.54 
MeOH 397 5157 514 0.06 
DMSO 397 4325 510 0.01 
H2O 403 3752 525 0.01 
In vacuumc 382  463  
18 toluene 381 7555 467 0.83 
dioxane 376 7023 470 0.67 
MeOH 379 7562 500 0.12 
DMSO 382 4399 504 0.01 
H2O 385 2740 510 0.03 
In vacuumc 371  446  
19 toluene 401 4476 494 0.52 
dioxane 404 5280 503 0.31 
 MeOH 411 3997 525 0.007 
 DMSO 395 3725 527 0.0003 
 H2O 402 3435 536 0.001 
 In vacuumc 391  483  
aMeasured in duplicate at a 12 M concentration, except for A1 that was 
measured at a 7.5 M. bQuantum yields calculated with reference to quinine 
sulfate (in 0.1 M H2SO4), except for 17 and 19, that were calculated with 
reference to coumarin 102 (in EtOH). cTD-DFT calculations in vacuum.                                                                                                                             
this shift was 32 nm), along with a 22-fold decrease in the 
quantum yield, which in A1 was insignificant. On the other 
hand, introduction of a Cl at position 2 (18 vs 16 and 19 vs 17) 
produced an additional shift to the red of 7-12 nm, and a 
phosphonate group at position 3 (16 vs 17 and 18 vs 19) an 
additional shift of 22-29 nm. These substitutions also 
enhanced the sensitivity to the solvent polarity. For instance, 
the quantum yield of 19 decreases 520-fold from toluene ( = 
0.52) to water ( = 0.001). However, no significant influence of 
the substituent at the imide nitrogen atom (for example, 16 vs 
20 and 19 vs 21) was observed in the photophysical properties. 
As a consequence of the red-shifts in the max
em, quinolimides 
16-19 present larger Stokes shifts (30-45 nm larger in toluene 
and 46-58 nm in water) than the naphthalimide A1. Similarly 
to this reference compound, the fluorescence of the 
quinolimide 16 in dioxane did not decreased after 1h of 
irradiation at the max
abs (372 nm), demonstrating the high 
photostability of the fluorophore (Figure S1 of Supplementary 
Information). In addition, the quinolimide 16 displayed a 3.2-
fold higher solubility in water13 than the naphthalimide A1. 
TD-DFT calculations at the PBE0/6-31+G(d,p) 
computational level14 have been carried out within the 
Gaussian-09 program15 to model the photophysical properties 
of compounds A1 and 16-19. The computational level used 
provided an adequate description of the UV and fluorescence 
spectra of quinolimide derivatives16. The calculated max
abs and 
max
em (Table 1) present excellent linear correlations with the 
experimental values in toluene (R2 = 0.99 and 0.99, 
respectively, see Supplementary Information). Based on the 
calculations, both frontier orbitals HOMO and LUMO (Table S2 
of Supplementary Information) are involved in absorption and 
fluorescence transitions, although the energetic value of the 
LUMO orbital is more affected by the structural differences of 
these compounds than the HOMO. The comparison of the 
geometrical parameters for both S0 and S1 states of 
compounds A1 and 16-19 shows a similar behavior with 
alternating variations in bond lengths along the tricyclic 
structure (shown for 16 in Figure S3). 
We next asked whether the bromomethyl acetamide 29
could serve to report on the interaction between the C helix-
derived peptide of CDK5 (GVPSSALREICLLK, K5 peptide) and 
the interacting alpha helix in p25 (KEAFWDRCLSVINLM, p25 
peptide). As shown in Figure 2A, titration of 5 µM 29-labelled-
K5 peptide with the p25 peptide yielded a 14.7-fold increase in 
fluorescence emission intensity (21.8-fold at saturation) of this 
probe with a Kd value of 355.0 µM ± 57. Moreover, this 
interaction lead to a shift in the emission maximum of probe 
29 from 541 to 450 nm, whereas the same experiment 
performed with an irrelevant peptide derived from ubiquitin 
had no effect on fluorescence emission of 29-labelled-K5 
peptide (Figure S4), indicating that the probe does not 
contribute to promote a false interaction. In comparison, the 
fluoresceine (FITC) labelled K5 peptide only yielded a 1.6-fold 
increase in fluorescence enhancement, with no associated 
spectral shift (Figure 2B). These results reveal that the 
quinolimide derivative 29 is a highly sensitive probe for 
monitoring interactions between peptides. 
Fig. 2 A) Titration of 5 µM 29-labelled CDK5 peptide with p25 peptide (ex= 390 
nm) and curve fit. B) Titration of 200 nM FITC-labelled CDK5 peptide with p25 
peptide (ex= 495nm) and curve fit. 
Finally, we asked whether the 29-labelled-K5 peptide could 
serve as a probe to colocalize endogenous p25 in the U87 
glioblastoma cell line when conjugated to the CDK5 peptide. 
As expected, the CDK5 29-labelled peptide did not enter cells 
alone. We therefore used a Pep-CDK5 peptide 
(KETWWETWWTEKK-GVPSSALREICLLK), which bears an N-
terminal fusion of the Pep1 cell-penetrating peptide17 linked to 
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the CDK5 peptide, and found that it penetrated readily into 
living U87 cells (Figure S5). To address whether the 29-labelled 
Pep-CDK5 peptide indeed colocalized with endogenous p25, 
we performed indirect immunofluorescence of U87 cells 
overlaid with the 29-labelled Pep-CDK5 peptide (Figure 3). 
These experiments revealed a complete overlay of the 29
signal observed through the GFP filter and of the signal 
revealed with Alexa647-labelled secondary/anti-p25 primary 
antibodies (Figure 3A). In contrast, cells which had not been 
overlaid with the 29-labelled peptide did not reveal any signal 
through the GFP channel (Figure 3B). 
Fig. 3 Labelled CDK5 peptide colocalizes with intracellular p25 in U87 cells. A) 29-
Labelled Pep-CDK5 peptide observed through the GFP filter was found to 
colocalize with p25 detected by immunofluorescence using Alexa647 secondary 
antibodies. B) Not ovelaid with 29-labelled peptide. 
In conclusion, we have synthesized solvatochromic 
naphthalimide-quinoline hybrid fluorophores that show higher 
solvatochromic behavior and fluorescence emission red-shift 
than known naphthalimide analogues. Additionally, 
quinolimide derivatives display large Stokes shifts, 
photostability and 3.2-fold higher kinetic solubility in water 
than naphthalimides. The novel fluorophores have been 
incorporated into amino acid derivatives, as tools for the 
preparation of fluorophore-containing peptides, and into thiol-
reactive compounds for protein labeling at cysteine. 
Conjugation of one of these quinolimide-based fluorophores 
to a CDK5 derived peptide has allowed to monitor the 
interaction between two peptides derived from the main 
interface between the catalytic kinase subunit CDK5 and its 
regulatory subunit p25, respectively. Finally, we have 
successfully employed the quinolimide-labelled peptide 
derived from the main interface of CDK5 with its regulatory 
partner p25 to probe endogenous p25 in living cells, revealing 
that this probe is sufficiently sensitive for detection of 
endogenous p25 protein, and further emphasizing the 
potential of quinolimides for cellular imaging applications. 
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